title: A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
abstract: What's known on the subject? and What does the study add? Lower urinary tract symptoms (LUTS) resulting from benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) are common problems in the aging male population. Moreover, several recent studies have shown that ED is closely associated with the presence and severity of LUTS independently of co-morbidities. However, the pathophysiological mechanisms linking LUTS/BPH and ED remain largely unexplored. The major difficulty in studying such relationships between ED and LUTS/BPH, and of exploring the impact of new therapeutic approaches for both LUTS/BPH and ED, is the lack of experimental model combining ED, prostate enlargement and bladder dysfunction all at once. The present study describes a new model of BPH, the SHR supplemented with testosterone which is the first animal model which displays all at once the key features of BPH: prostate enlargement and an increased sympathetic tone of bladder outlet mimicking the static and the dynamic components of voiding symptoms of BPH, a significant impairment of bladder function which reflects the storage symptoms of BPH and finally, ED. This model could be very relevant to better characterize the close relationship that exists between BPH/LUTS and ED, and to evaluate new therapeutic strategies for BPH together with their side effect profile on sexual function on the same animal, thus allowing a reduction of the number of animals to be used in such studies. Study Type - Aetiology (case control) Level of Evidence 3b.
  
  
  OBJECTIVE
  • To design a new experimental model combining erectile dysfunction, prostate enlargement and urodynamic impairment characteristic of lower urinary tract symptoms (LUTS) associated with benign prostate hyperplasia (BPH).
  
  
  METHODS
  • Three groups of animals (12-week-old; n= 7/group) were considered: Wistar Kyoto (control) rats (WKY), untreated spontaneously hypertensive rats (SHR) and SHR treated with testosterone (SHR-T, 3 mg/kg/day) for 3 weeks. • Cystometry experiments and evaluation of erectile function were performed. Prostate enlargement was evaluated.
  
  
  RESULTS
  • SHR displayed a significant decrease in the intercontraction interval (ICI) and in the voided volume (VV) whereas non-voiding contractions (NVC) were increased. SHR-T exhibited a further decreased ICI and VV and an increased frequency of NVC. • Erectile responses to electrical stimulation of the cavernous nerve were significantly impaired in both SHR (-66%) and SHR-T (-58%). • The prostate weight was similar in WKY and SHR, but significantly increased in SHR-T.
  
  
  CONCLUSIONS
  • The testosterone-supplemented SHR represents an experimental model for urodynamic impairment combining both static and dynamic components of voiding symptoms with erectile dysfunction and prostate enlargement. • This model is suitable for the assessment of sexual side effects of LUTS/BPH treatments and efficacy of new therapeutic agents in LUTS/BPH and associated erectile dysfunction.
authors.affiliation: Pelvipharm, Orsay, France.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Oudot
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Oger
authors.forename: Delphine
authors.initials: D
authors.lastname: Behr-Roussel
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Caisey
authors.forename: Jacques
authors.initials: J
authors.lastname: Bernabé
authors.forename: Laurent
authors.initials: L
authors.lastname: Alexandre
authors.forename: François
authors.initials: F
authors.lastname: Giuliano
mesh_terms: D000704:Analysis of Variance; D000728:Androgens / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D062186:Arterial Pressure / Q000502:physiology; D004195:Disease Models, Animal; D004558:Electric Stimulation; D007172:Erectile Dysfunction / Q000209:etiology* / Q000503:physiopathology; D059411:Lower Urinary Tract Symptoms / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D011312:Pressure; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000503:physiopathology; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D013739:Testosterone / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000728:Androgens; D013739:Testosterone